{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001491","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.652357+00:00","generated_at":"2026-05-24T17:21:37.620328+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Aptose regains Nasdaq minimum bid price compliance; equity rule still breached","bullets":["Nasdaq confirmed closing bid price at or above $1.00 for 10 consecutive business days as of March 14, 2025.","Aptose remains non-compliant with Nasdaq's $2.5M shareholders' equity requirement.","Company operates under a Hearing Panel exception to regain equity compliance, but no assurance of success.","Aptose is a clinical-stage precision oncology firm developing tuspetinib-based triple therapy for newly diagnosed AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001491","json":"https://secwatch.observer/filing/0001171843-25-001491.json","markdown":"https://secwatch.observer/filing/0001171843-25-001491.md","text":"https://secwatch.observer/filing/0001171843-25-001491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/0001171843-25-001491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/f8k_031725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T17:21:37.620328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}